In this article
This section covers the opening paragraph about the current state of cervical cancer in the United States, including statistics on new cases, deaths, and which populations are most affected. It establishes why screening matters and who is most at risk.
In the past, the recommendation for women of this age group was a cervical smear, also known as exfoliative cytology, a cervical smear every three years or combined with an HPV test every five years (co-testing). Women can still choose to use this method to screen for cervical cancer. For women aged 21-29, it is still recommended to have a Pap smear every three years. It is not recommended for women under 21 years of age because cervical cancer under the age of 21 is rare. Similarly, women who are adequately screened for cervical cancer over the age of 65 do not need to be tested. Those who are over 65 years old and have had 3 cervical smears or 2 joint examinations have no adverse results, nor have they had any adverse results in the past 10 years, and they no longer need to undergo cervical cancer screening, even if they have a new sex partner. The new guidelines are only for women who do not have any bad test results. People who have been diagnosed with highly premalignant lesions or cervical cancer should consult their doctor to discuss their detection methods.
The United States Preventive Services Task Force (USPSTF) provides new recommendations for cervical cancer screening and provides women with more testing options. The biggest change is that women between the ages of 30-65 can choose to completely abandon cervical smears. New evidence shows that human papillomavirus (HPV) is sexually transmitted and almost all cervical cancer is caused by HPV. HPV causes changes in cervical cells, which can lead to cervical cancer. Women aged 30-65 years can choose to have an HPV test every five years to screen for cervical cancer, instead of having a cervical smear every three years. Avoid unnecessary tests. Thus avoiding additional costs and more follow-up problems. This is the first time that a separate HPV test is recommended to screen for cervical cancer, and this test is recommended regardless of sexual history. But Bruder predicts that Pap smears will not be replaced soon.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
β Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.